ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.
Njira L. Lugogo, MD, MS
Advertisement
Njira Lugogo, MD, MS, is the director of the Division of Pulmonary & Critical Care Medicine's Asthma Program at the University of Michigan Health.
Articles by Njira L. Lugogo, MD, MS
PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.
PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5